Hospital Acquired Infections Testing Kits Global Market Report 2024

The hospital acquired infections testing kits market size has grown strongly in recent years. It will grow from $4.35 billion in 2023 to $4.7 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The expansion observed in the historical period can be ascribed to the rise in hospital-acquired infections (HAIs), the growing aging population, and an increased number of surgeries.

The hospital acquired infections testing kits market size is expected to see strong growth in the next few years. It will grow to $6.42 billion in 2028 at a compound annual growth rate (CAGR) of 8.1%. The anticipated growth in the forecast period is linked to an increase in chronic diseases, a surge in healthcare expenditure, and growing government support, which will propel the expansion of the market. Key trends expected in the forecast period involve collaborations with artificial intelligence companies, seeking assistance from the government, integrating big data into market analysis, and forming partnerships with other players in the market.

The incidence of hospital-acquired infections (HAIs) is on the rise, impacting both inpatients and outpatients. Hospital-acquired infections, or nosocomial infections, refer to diseases acquired in hospitals and medical clinics. For example, according to the Center for Disease Control and Prevention findings, approximately 1.7 million people in the USA acquire hospital-acquired infections while being admitted for other health issues, with over 98,000 patients (around 5%) succumbing to these infections. The increasing prevalence of hospital-acquired infections contributes to a growing demand for hospital-acquired infections testing kits in the market.

The increasing number of healthcare settings is expected to drive the growth of the hospital-acquired infections testing kits market in the future. Within a healthcare setting, diverse healthcare facilities and services are available, including acute care hospitals, urgent care centers, rehabilitation facilities, nursing homes, and long-term care facilities, collectively providing comprehensive healthcare solutions. Hospital-acquired infections testing kits play a crucial role in detecting and preventing nosocomial infections, thereby enhancing patient safety in healthcare facilities. For instance, in May 2023, according to the American Hospital Association, the total number of hospitals in the U.S. region saw a significant increase from 6,093 in 2022 to 60,129 in 2023. Additionally, admissions in community hospitals also experienced growth, rising from 31,393,318 in 2022 to 31,967,073 in 2023. Therefore, the increasing number of healthcare settings propels the hospital-acquired infections testing kits market.

Advancements in diagnostic tests for diagnosing Hospital-Acquired Infections (HAIs), such as flow cytometry, mass spectrometry, near-infrared spectroscopy, and nucleic acid-based technologies, are enhancing accuracy and providing more precise data. Mass spectrometers, in particular, have seen significant progress, quantified known materials and identified unknown compounds within a sample. For instance, SCIEX's X500 QTOF addresses contamination challenges, offering a compact device without compromising resolution and accuracy. It provides quicker results, enabling operators to make data-driven decisions promptly.

Government agencies, such as the US FDA (Food and Drug Administration) in the USA and the European Medicines Agency/Committee in the European Region, regulate hospital-acquired infections testing kits. These regulatory bodies establish guidelines concerning the safety, efficiency, and efficacy of the instruments within the hospital-acquired infection testing kits market. Manufacturers and service providers must adhere to the CBER Regulations published in the first chapter of Title 21 of CFR. Part 600 of CFR 21 focuses on established standards, including sample retention conditions, required shipment temperatures, equipment sterilization, and the responsibilities of inspectors in laboratory inspections. The regulation also allows manufacturers to report any deviations of their product from its intended purpose. CBER operates under the FDA (Food and Drug Administration). Additionally, the Code of Federal Regulations, Title 21, Part 866, outlines regulations related to immunology and microbiology devices, used for identifying infections caused by bacteria and various viruses.

Major companies operating in the hospital acquired infections testing kits market report are Becton, Dickinson and Company, Abbott Laboratories, Cepheid, F. Hoffmann-La Roche Ltd., Hologic, Inc., STERIS PLC, QIAGEN, Meridian Bioscience Inc., BioMérieux SA, Metall Zug (Belimed Group), Innovaccer, JD Health, CISCO Systems Inc., GE Healthcare, Honeywell Lifesciences, Zydus Cadila, ImmunoScience, CPC Diagnostics, Seegene, SD Biosensor, Vivacheck Lab, Fujirebio, Sysmex Corporation, Philip Healthcare, Getein Biotech, Hangzhou Biotest Biotech, AmonMed Biotechnology, Beijing Tigsun Diagnostics, Hunan Lituo Biotechnology, Bayer AG, Cantel Medical Corporation, BioMérieux, Siemens Healthineers.

North America was the largest region in the hospital-acquired infections testing kits market in 2023. Western Europe was the second largest region in the global hospital-acquired infections testing kits market share. The regions covered in the hospital acquired infections testing kits market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the hospital acquired infections testing kits market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain. The hospital-acquired infections testing kits market consist of sales of testing kits and devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The primary components of hospital-acquired infection testing kits include instruments, reagents, and consumables. Instruments for these testing kits encompass various tools essential for hospital-acquired infections testing, aiding scientists in cultivating new cells in culture media for purposes such as drug development, tissue culture, engineering, gene therapy, vaccine production, and toxicity testing. Hospital-acquired infections testing kits address pathogens such as viruses, bacteria, and fungi through sterilization, chemical treatments, and radiation methods. The testing extends to identifying infections such as pneumonia, urinary tract infection, bloodstream infection, surgical site infection, MRSA infection, and others. These kits find applications in drug-resistance testing and disease testing.

The hospital-acquired infections testing kits market research report is one of a series of new reports that provides hospital-acquired infections testing kits market statistics, including hospital-acquired infections testing kits industry global market size, regional shares, competitors with a hospital-acquired infections testing kits market share, detailed hospital-acquired infections testing kits market segments, hospital-acquired infections testing kits market trends and opportunities, and any further data you may need to thrive in the hospital-acquired infections testing kits industry. This hospital-acquired infections testing kits market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.